Exhibit 107
Calculation of Fee Filing Tables
Form S-3
(Form Type)
Stoke Therapeutics, Inc.
(Exact name of Registration as Specified in its Charter)
Table 1 – Newly Registered and Carry Forward Securities
| Security Type | Security Class Title | Fee Calculation or Carry Forward Rule | Amount Registered | Proposed Maximum Offering Price Per Unit | Maximum Aggregate Offering Price | Fee Rate | Amount of Registration Fee | Carry Forward Form Type | Carry Forward File Number | Carry Forward Initial Effective Date | Filing Fee Previously Paid in Connection with Unsold Securities to be Carried Forward | |||||||||||||
Newly Registered Securities | ||||||||||||||||||||||||
| Fees to be Paid | Equity | Common stock, par value $0.0001 per share | 457(o) | |||||||||||||||||||||
| Equity | Preferred stock, par value $0.0001 per share | 457(o) | ||||||||||||||||||||||
| Debt | Debt securities | 457(o) | ||||||||||||||||||||||
| Other | Warrants | 457(o) | ||||||||||||||||||||||
| Other | Subscription Rights | 457(o) | ||||||||||||||||||||||
| Other | Units | 457(o) | ||||||||||||||||||||||
Unallocated (Universal) Shelf | — | 457(o) | $158,632,167(1) | N/A(2) | $158,632,167 | $0.0000927 | $14,706 | |||||||||||||||||
Carry Forward Securities | ||||||||||||||||||||||||
| Carry Forward Securities | Equity | Common stock, par value $0.0001 per share | 415(a)(6) | |||||||||||||||||||||
| Equity | Preferred stock, par value $0.0001 per share | 415(a)(6) | ||||||||||||||||||||||
| Debt | Debt securities | 415(a)(6) | ||||||||||||||||||||||
| Other | Warrants | 415(a)(6) | ||||||||||||||||||||||
| Other | Subscription Rights | 415(a)(6) | ||||||||||||||||||||||
| Other | Units | 415(a)(6) | ||||||||||||||||||||||
Unallocated (Universal) Shelf | — | 415(a)(6) | $241,367,833(1) | N/A(2) | $241,367,833 | $0.0001298 | S-3 | 333-239801 | July 20, 2020 | $31,330 | ||||||||||||||
| Total Offering Amounts | $400,000,000(3) | |||||||||||||||||||||||
| Total Fees Previously Paid | — | |||||||||||||||||||||||
| Total Fee Offsets | — | |||||||||||||||||||||||
| Net Fee Due | $14,706 | |||||||||||||||||||||||
| (1) | There is being registered hereunder an unspecified number of shares of (a) common stock, (b) preferred stock, (c) debt securities, (d) warrants to purchase common stock, preferred stock or debt securities of the Registrant, (e) subscription rights to purchase common stock, preferred stock or debt securities of the Registrant, and (f) units, consisting of some or all of these securities in any combination, as may be sold from time to time by the Registrant. Any securities registered hereunder may be sold separately or as units with other securities registered hereunder. There is also being registered hereunder an unspecified number of shares of common stock, preferred stock and debt securities as shall be issuable upon conversion, exchange or exercise of any securities that provide for such issuance. In no event will the aggregate offering price of all types of securities issued by the Registrant pursuant to this registration statement exceed $400,000,000. Pursuant to Rule 416(a) under the Securities Act of 1933, as amended, or the Securities Act, this registration statement also covers any additional securities that may be offered or issued in connection with any stock split, stock dividend or similar transaction. |
| (2) | The proposed maximum offering price per share and proposed maximum aggregate offering price for each type of security will be determined from time to time by the Registrant in connection with the issuance by the Registrant of the securities registered hereunder and is not specified as to each class of security pursuant to General Instruction II.D. of Form S-3 under the Securities Act. |
| (3) | The $400,000,000 of securities registered pursuant to this registration statement includes $241,367,833 of securities (the “Unsold Securities”) registered pursuant to the Registration Statement on Form S-3 (No. 333-239801), which became effective on July 20, 2020. Pursuant to Rule 415(a)(6) under the Securities Act, the filing fees previously paid in connection with the Unsold Securities will continue to be applied to the Unsold Securities. |
